Why Pharma Finally Bought AI Software

Why did pharma suddenly start signing massive software deals with AI biotech startups? We unpack the jump from protein structure prediction to binding affinity models, and how tools like Chai Discovery are turning molecular design into a more deterministic, engineering-like workflow. The episode also explores the rise of molecule CAD tools, the promise of one-shot antibody design, and the bigger question of whether software will reshape drug discovery or simply become the new layer pharma giants absorb.